SCHEMBL5162850

SCHEMBL5162850

N#CCC(=O)c1cc[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.35
KDM4E B2RXH2 5/20 0.33
KCNH2 Q12809 4/20 0.33
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
RECQL P46063 1/20 0.33
MCL1 Q07820 2/20 0.32
HK1 P19367 1/20 0.31
HKDC1 Q2TB90 1/20 0.31
HSD17B10 Q99714 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12094843 0.75
SCHEMBL29171446 0.75
SCHEMBL12881756 0.75
SCHEMBL10593169 0.74 CTSB (0.43) KDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL9823399 0.73 L3MBTL1 (0.41) MAPT
SCHEMBL30637154 0.73
SCHEMBL5161547 0.72 MEN1 (0.31) MAPTKDM4EMEN1KMT2AGAA
SCHEMBL9101778 0.72 HSD17B3 (0.41) ALDH1A1SMN1; SMN2RECQLHSD17B10
Water SCHEMBL28134075 0.71
SCHEMBL5325515 0.71 CES2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20040019221-A1 Processes for the preparation of pyrazole compounds NIPPON SODA CO., LTD. (JP) 2004-01-29 US disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed
EP-1318145-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE COMPOUNDS NIPPON SODA CO., LTD. (JP) 2003-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019221-A1 Processes for the preparation of pyrazole compounds CBR1, CPS1, CYC1 MAPT 4755/4885KDM4E 3571/4885KCNH2 371/4885
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO MAPT 4661/4885KDM4E 862/4885KCNH2 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.